Certolizumab pegol (Cimzia) (subcutaneous injection)
The objective of this review is to perform a systematic review of the beneficial and harmful effects of certolizumab pegol (CZP) for the treatment of active ankylosing spondylitis (AS) in adults who have had an inadequate response to conventional therapy
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
CADTH
September 2017, 2017
|
| Series: | Common drug review clinical review report
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this review is to perform a systematic review of the beneficial and harmful effects of certolizumab pegol (CZP) for the treatment of active ankylosing spondylitis (AS) in adults who have had an inadequate response to conventional therapy |
|---|---|
| Physical Description: | 1 PDF file (vi, 101 pages) illustrations |